Open Access

Efficient pre‑treatment for pancreatic cancer using chloroquine‑loaded nanoparticles targeting pancreatic stellate cells

  • Authors:
    • Sokichi Matsumoto
    • Kohei Nakata
    • Akiko Sagara
    • Weiyu Guan
    • Naoki Ikenaga
    • Kenoki Ohuchida
    • Masafumi Nakamura
  • View Affiliations

  • Published online on: July 1, 2021     https://doi.org/10.3892/ol.2021.12894
  • Article Number: 633
  • Copyright: © Matsumoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pancreatic stellate cells (PSCs) play a key role in desmoplastic stroma, which is a characteristic of pancreatic ductal adenocarcinoma (PDAC), and they also enhance the malignancy of pancreatic cancer cells. Our previous study reported chloroquine's mitigating effects on PSC activation; however, the drug is known to induce adverse effects in clinical practice. The present study aimed to reduce chloroquine doses and develop a useful pre‑treatment that targets PSCs using nanoparticles. Poly lactic‑co‑glycolic acid (PLGA) nanoparticles were used as carriers and loaded with indocyanine green (Nano‑ICG) or chloroquine (Nano‑CQ). Tumor accumulation of Nano‑ICG was evaluated using an in vivo imaging system. The effects of chloroquine, Nano‑CQ and/or chemotherapy drug gemcitabine were investigated in an orthotopic xenograft mouse model. Nano‑ICG selectively accumulated in pancreatic tumors and persisted therein for over 7 days after administration. Additionally, Nano‑ICG accumulated in the peritoneal metastasized regions, but not in the liver, kidney and normal pancreatic tissues. Nano‑CQ reduced the density of activated PSCs at lower chloroquine doses and significantly restrained tumor progression in combination with gemcitabine. In conclusion, the PLGA nanosystem successfully delivered the drug to pancreatic tumors. Nano‑CQ efficiently reduced PSC activation and may be a promising novel pre‑treatment strategy for PDAC.8
View Figures
View References

Related Articles

Journal Cover

August-2021
Volume 22 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Matsumoto S, Nakata K, Sagara A, Guan W, Ikenaga N, Ohuchida K and Nakamura M: Efficient pre‑treatment for pancreatic cancer using chloroquine‑loaded nanoparticles targeting pancreatic stellate cells. Oncol Lett 22: 633, 2021.
APA
Matsumoto, S., Nakata, K., Sagara, A., Guan, W., Ikenaga, N., Ohuchida, K., & Nakamura, M. (2021). Efficient pre‑treatment for pancreatic cancer using chloroquine‑loaded nanoparticles targeting pancreatic stellate cells. Oncology Letters, 22, 633. https://doi.org/10.3892/ol.2021.12894
MLA
Matsumoto, S., Nakata, K., Sagara, A., Guan, W., Ikenaga, N., Ohuchida, K., Nakamura, M."Efficient pre‑treatment for pancreatic cancer using chloroquine‑loaded nanoparticles targeting pancreatic stellate cells". Oncology Letters 22.2 (2021): 633.
Chicago
Matsumoto, S., Nakata, K., Sagara, A., Guan, W., Ikenaga, N., Ohuchida, K., Nakamura, M."Efficient pre‑treatment for pancreatic cancer using chloroquine‑loaded nanoparticles targeting pancreatic stellate cells". Oncology Letters 22, no. 2 (2021): 633. https://doi.org/10.3892/ol.2021.12894